US 11707536
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
granted A61KA61K31/711A61K48/0058
Quick answer
US patent 11707536 (Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A) held by Takeda Pharmaceutical Company Limited expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/711, A61K48/0058, A61K48/0066, A61P